ResearcherInsermNo recent work listed
S. Gourgou-Bourgade
Matched on OpenAlex author ID A5004937624. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 43
2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper
Papers 5
- A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort. First author DOI 10.1186/s12885-018-4906-4↗
- An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.12761↗
- Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to… Co-author DOI 10.1016/j.ejca.2014.07.011↗
- Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomize… Co-author DOI 10.1200/jco.2012.44.4869↗
- FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. Co-author DOI 10.1056/nejmoa1011923↗
Closest collaborators
The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Thierry Conroy · 4 shared papers, 2011–2016 · strength 0.14
- Paper An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. DOI 10.18632/oncotarget.12761↗
- Paper Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: result… DOI 10.1200/jco.2012.44.4869↗
- Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗
- Marc Ychou · 3 shared papers, 2011–2016 · strength 0.11
- Paper An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. DOI 10.18632/oncotarget.12761↗
- Paper Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: result… DOI 10.1200/jco.2012.44.4869↗
- Paper FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. DOI 10.1056/nejmoa1011923↗
- Eric Assénat · 2 shared papers, 2011–2018 · strength 0.08
- Bertrand Napoléon · 1 shared paper, 2018 · strength 0.06
- V. Vendrely · 1 shared paper, 2018 · strength 0.06
- Stéphanie Truant · 1 shared paper, 2018 · strength 0.06
- Dominique Farge · 1 shared paper, 2018 · strength 0.06
- Cindy Canivet · 1 shared paper, 2018 · strength 0.06
- Louis Buscail · 1 shared paper, 2018 · strength 0.06
- Barbara Bournet · 1 shared paper, 2018 · strength 0.06
- Julien Péron · 1 shared paper, 2016 · strength 0.06
- Marc E Buyse · 1 shared paper, 2016 · strength 0.06
- Antoine Adenis · 2 shared papers, 2011–2013 · strength 0.05
- Jean‐Luc Raoul · 2 shared papers, 2011–2013 · strength 0.05
- Olivier Bouché · 2 shared papers, 2011–2013 · strength 0.05
- Michel Pierre Ducreux · 2 shared papers, 2011–2014 · strength 0.05
- Franck Bonnetain · 1 shared paper, 2014 · strength 0.03
- Christos Dervenis · 1 shared paper, 2014 · strength 0.03
- Laëtitia Dahan · 1 shared paper, 2014 · strength 0.03
- Emmanuel Mitry · 1 shared paper, 2014 · strength 0.03
- Patrick Pessaux · 1 shared paper, 2014 · strength 0.03
- Roberto Labianca · 1 shared paper, 2014 · strength 0.03
- Jean‐Robert Delpéro · 1 shared paper, 2014 · strength 0.03
- Paula Ghaneh · 1 shared paper, 2014 · strength 0.03
- Josep M. Tabernero · 1 shared paper, 2014 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.